Intravitreal aflibercept 8 mg in patients from Japan with neovascular age-related macular degeneration: 48-week subgroup analysis of the PULSAR trial.
Hideki Koizumi, Shigeru Honda, Tsutomu Yasukawa, Genichiro Kishino, Tetsuju Sekiryu, Andrea Schulze, Takuto Yamashita, Ursula Schmidt-Ott, Min Zhao, Xin Zhang, Alyson J Berliner, Karen W Chu, Kimberly Reed, Yenchieh Cheng, Rafia Bhore, Robert Vitti, Ikuko Fujita, Sergio Leal, Tomohiro Iida, PULSAR investigators
Jpn J Ophthalmol 70(1) 139-149
摘要
摘要
PURPOSE: To evaluate the 1-year efficacy and safety of aflibercept 8 mg compared with aflibercept 2 mg in a pre-specified analysis of patients from Japan with neovascular age-related macular degeneration (nAMD) included in PULSAR. STUDY DESIGN: PULSAR (NCT04423718) was a global, phase 3, randomized, double-masked, non-inferiority study of adults with nAMD. Patients were randomized 1:1:1 to receive aflibercept 8 mg every 12 weeks (8q12), or every 16 weeks (8q16), or aflibercept 2 mg every 8 weeks (2q8), following three initial monthly doses in all groups. METHODS: This subgroup analysis of Japan and non-Japan cohorts from PULSAR evaluated changes from baseline in best-corrected visual acuity (BCVA), central subfield retinal thickness, durability and safety outcomes. RESULTS: In the Japan subgroup, least squares (LS) mean (95% CI) changes from baseline in BCVA at week 48 were +6.5 (+0.7, +12.3), +7.9 (+5.1, +10.6), and +4.7 (-0.5, +9.9) letters for patients in the 8q12 (n = 31), 8q16 (n = 33), and 2q8 (n = 33) groups, respectively. The majority of patients in the 8q12 (82.1%) and 8q16 (93.8%) groups maintained their randomized dosing intervals through Week 48. Ocular treatment-emergent adverse events were reported in 35.5%, 30.3%, and 39.4% of patients in the Japan subgroup in 8q12, 8q16, and 2q8 groups, respectively. Similar efficacy and safety results were observed in the non-Japan subgroup. CONCLUSION: Aflibercept 8 mg has similar efficacy and safety to aflibercept 2 mg when administered at extended dosing intervals in both the Japan and non-Japan subgroups, consistent with the overall PULSAR results.
KM 提取结果
0 个 Figure · 0 个 KM 面板
其他 Figure(4,默认折叠)
这些图片未产生 KM 曲线结果,不在主页面重复展示。